TargetMol

Clozapine

Product Code:
 
TAR-T0455
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0455-50mg50mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0455-100mg100mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0455-200mg200mg£210.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0455-500mg500mg£333.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0455-1g1g£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Clozapine is a tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity.
CAS:
5786-21-0
Formula:
C18H19ClN4
Molecular Weight:
326.83
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9993
SMILES:
CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12
Target:
Dopamine Receptor; Adrenergic Receptor; AChR

References

1. Robertson GS, et al. Neuroscience, 1992, 46(2), 315-328. 2. Nguyen TV, et al. Proc Natl Acad Sci U S A, 1992, 89(10), 4270-4274. 3. Brunello N, et al. Neuropsychopharmacology, 1995, 13(3), 177-213. 4. Arvanov VL, et al. J Pharmacol Exp Ther, 1997, 283(1), 226-234. 5. Zorn SH, et al. Eur J Pharmacol, 1994, 269(3), R1-2.